Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK10 | P53779 | 11/20 | 0.65 |
| ▸ | MAPK8 | P45983 | 10/20 | 0.65 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.65 |
| ▸ | PIP5K1C | O60331 | 5/20 | 0.62 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.62 |
| ▸ | PIP5K1B | O14986 | 2/20 | 0.62 |
| ▸ | PIP5K1A | Q99755 | 2/20 | 0.62 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.58 |
| ▸ | BUB1 | O43683 | 3/20 | 0.52 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.51 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.51 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.51 |
| ▸ | PI4KA | P42356 | 1/20 | 0.51 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.51 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.51 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.51 |
| ▸ | GSK3B | P49841 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6037695 | 0.95 | MAPK10 (0.62) | MAPK10MAPK8MAPK14PIP5K1CPIK3CA | |
| SCHEMBL1519020 | 0.85 | MAPK10 (0.76) | MAPK10MAPK8MAPK14PIP5K1CPIK3CA | |
| SCHEMBL1518956 | 0.83 | MAPK10 (0.78) | MAPK10MAPK8MAPK14PIP5K1CPIK3CA | |
| SCHEMBL1518759 | 0.82 | MAPK10 (0.56) | MAPK10MAPK8MAPK14PIP5K1CPIK3CA | |
| SCHEMBL1518951 | 0.81 | BUB1 (0.67) | MAPK10MAPK8MAPK14PIP5K1CPIK3CA | |
| SCHEMBL1518953 | 0.81 | BUB1 (0.67) | MAPK10MAPK8MAPK14PIP5K1CPIK3CA | |
| SCHEMBL1519003 | 0.79 | MAPK10 (1.00) | MAPK10MAPK8MAPK14PIP5K1CPIK3CA | |
| SCHEMBL3331893 | 0.78 | NPC1 (0.50) | GSK3B | |
| SCHEMBL5754037 | 0.78 | NPC1 (0.50) | GSK3B | |
| SCHEMBL1518883 | 0.78 | MAPK10 (0.72) | MAPK10MAPK8MAPK14PIP5K1CPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004052880-A1 | PYRIDINE DERIVATIVES AS JNK INHIBITORS AND THEIR USE | ASTRAZENECA AB (SE) | 2004-06-24 | — | — | WO | claimed |
| US-20150313881-A1 | Therapeutic Methods for Type I Diabetes | UNIVERSITY OF MASSACHUSETTS | 2015-11-05 | — | — | US | disclosed |
| US-8501812-B2 | Therapeutic methods for type I diabetes | UNIVERSITY OF MASSACHUSETTS (US) | 2013-08-06 | — | — | US | disclosed |
| US-20120208846-A1 | Therapeutic Methods For Type I Diabetes | UNIVERSITY OF MASSACHUSETTS | 2012-08-16 | — | — | US | disclosed |
| WO-2006104983-A1 | THERAPEUTIC METHODS FOR TYPE I DIABETES | UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL (US) | 2006-10-05 | — | — | WO | disclosed |
| WO-2004052880-A1 | PYRIDINE DERIVATIVES AS JNK INHIBITORS AND THEIR USE | ASTRAZENECA AB (SE) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150313881-A1 | Therapeutic Methods for Type I Diabetes | MAPK9, IAPP, RNASE1 | MAPK10 12/4885MAPK8 25/4885MAPK14 56/4885 |
| US-20120208846-A1 | Therapeutic Methods For Type I Diabetes | MAPK9, IAPP, RNASE1 | MAPK10 12/4885MAPK8 25/4885MAPK14 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.